Antidepressants act on glial cells: SSRIs and serotonin elicit astrocyte calcium signaling in the mouse prefrontal cortex.
One important target in the treatment of major depressive disorder (MDD) is the serotonin (5-hydroxytryptamine, 5-HT) system. Selective serotonin reuptake inhibitors (SSRI) are used to treat MDD. Yet, the mode of action of these drugs is not completely understood. There is evolving evidence for a role of glutamate in mood disorder and its signaling. Astrocytes are involved in glutamate metabolism and play an active role in memory processing but their role in mood disorders is still largely unknown. A modulation of astrocytic signaling by SSRIs or 5-HT has not been investigated up to now. We investigated astrocytic calcium signaling with the calcium indicator dye Fluo-4. Using a confocal microscope, we imaged astrocytes in the medial prefrontal cortex of acute mouse brain slices after the application of the SSRIs citalopram and fluoxetine. In the same way, we studied the effects of serotonin and the modulation of this signaling by glutamate in astrocytes. We found that astrocyte calcium signaling can be elicited by 5-HT. Also, the SSRIs citalopram and fluoxetine induce calcium signals in about 1/3 of all astrocytes, even when neuronal signal propagation is inhibited. Astrocytic responses to 5-HT have a unique pattern and they could mostly not be evoked twice. We determined that glutamate is a substance that can interfere with 5-HT-induced calcium signals in astrocytes since after stimulation by glutamate, astrocytes did not show a response to 5-HT. Astrocytic calcium signaling is elicited by SSRIs and 5-HT. They may serve as integrators, linking the serotonergic and glutamatergic signaling pathways.
Schipke
Carola G
CG
Department of Psychiatry, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Germany. carola.schipke@charite.de
Heuser
Isabella
I
Peters
Oliver
O
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000814:Aniline Compounds; D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects*; D020013:Calcium Signaling / Q000187:drug effects*; D015283:Citalopram / Q000494:pharmacology; D004347:Drug Interactions; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005473:Fluoxetine / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology; D066298:In Vitro Techniques; D051379:Mice; D017397:Prefrontal Cortex / Q000166:cytology*; D012701:Serotonin / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D026941:Sodium Channel Blockers / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology; D014966:Xanthenes
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D000814:Aniline Compounds; D015283:Citalopram; D018691:Excitatory Amino Acid Antagonists; D005473:Fluoxetine; D018698:Glutamic Acid; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D026941:Sodium Channel Blockers; D013779:Tetrodotoxin; D014966:Xanthenes; C409648:Fluo 4